To provide optimal patient care, hematologists, oncologists, nurses, pharmacists, and other health care professionals who treat patients with DLBCL and FL must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with NHL and the clinical utility of agents that could significantly impact patient outcomes. Community heme-oncs must be able to propose individualized strategies for treatment and to support their patients through the complex risk/benefit analyses involved in treatment decisions. As their patients progress through successive lines of therapy, heme-oncs must be able to plan effective therapy sequences to maximize survival and quality of life. The proposed program will support clinicians in the community setting by providing strategies, resources, and analysis that can be applied to improve care quality, thereby improving patient outcomes
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 384 Inverness Parkway
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedSep 29, 2025
-
Last day to claim creditOct 16, 2026 5 days left
-
PRIME Education, Inc. (PRIME®) Expert Strategies for Identifying Eligible Patients With DLBCL and FL for CAR T-Cell Therapy
-
The Society of Hematologic Oncology +1 The Society of Hematologic Oncology 2026 Fourteenth Annual Meeting
-
Answers in CME Inc. (AiCME) Where Do ADCs Fit in R/R DLBCL? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies
-
Plexus Communications +1 Implementing CAR T-Cell Therapies for B-Cell Lymphoma in the Community Setting: Steps to Success Empowering Peer-to-Peer Education
-
Plexus Communications +1 Navigating the Frontier of First-Line Treatments for FLT3-Mutated Acute Myeloid Leukemia
-
Plexus Communications +1 Subtype-Driven Therapy in DLBCL: The Emerging Role of Frontline BTK Inhibition
